Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)
September 06 2022 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced three oral presentations by academic collaborators at the
29th International Congress of The Transplantation Society (TTS
2022) being held September 10-14, 2022 in Buenos Aires, Argentina,
and virtually. Copies of the presentations will be available under
the Scientific Presentations tab of the Tonix website at
www.tonixpharma.com following the conference.
Oral Presentation Details
Title: |
Long-term
rejection free renal allograft survival with Fc-modified anti-CD154
antibody monotherapy in nonhuman primates |
Date: |
Monday,
September 12, 2022 |
Time: |
4:35 p.m.
EDT (17:35 ART) |
Session: |
Campfire
Session: Models, mechanisms & therapies |
Presenter |
Grace
Lassiter, M.D., Research Fellow of the Kawai Lab |
|
|
Title: |
Monotherapy with TNX-1500, a Fc-modified anti-CD154mAb,
prolongs cardiac allograft survival in cynomolgus monkeys |
Date: |
Tuesday,
September 13, 2022 |
Time: |
3:25 p.m.
EDT (16:25 ART) |
Session: |
Mini-Oral
Abstracts Session: Snap-shots of thoracic transplantation |
Presenter |
Kohei
Kinoshita, M.D., Research Fellow of the Pierson Lab |
|
|
Title: |
Long-term (>1 year) rejection/TMA free survival of kidney
xenografts with triple xenoantigen knockout and multiple human
transgenes in nonhuman primates |
Date: |
Wednesday,
September 14, 2022 |
Time: |
10:00 a.m
EDT (11:00 ART) |
Session: |
Mini-Oral
Abstracts Session: Xenotransplantation |
Presenter |
Grace
Lassiter, M.D., Research Fellow of the Kawai Lab |
Tonix Pharmaceuticals Holding
Corp.*
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix’s portfolio is composed of central nervous system
(CNS), rare disease, immunology and infectious disease product
candidates. Tonix’s CNS portfolio includes both small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine
HCl sublingual tablet), is in mid-Phase 3 development for the
management of fibromyalgia with a new Phase 3 study launched in the
second quarter of 2022 and interim data expected in the second
quarter of 2023. TNX-102 SL is also being developed to treat Long
COVID, a chronic post-acute COVID-19 condition. Tonix initiated a
Phase 2 study in Long COVID in the third quarter of 2022 and
expects interim data in the first half of 2023. TNX-1300 (cocaine
esterase) is a biologic designed to treat cocaine intoxication and
has been granted Breakthrough Therapy designation by the FDA. A
Phase 2 study of TNX-1300 is expected to be initiated in the first
quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a
small molecule in development for chronic migraine, is expected to
enter the clinic with a Phase 2 study in the fourth quarter of
2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal
potentiated oxytocin) for the treatment of Prader-Willi syndrome.
TNX-2900 has been granted Orphan Drug designation by the FDA.
Tonix’s immunology portfolio includes biologics to address organ
transplant rejection, autoimmunity and cancer, including TNX-1500,
which is a humanized monoclonal antibody targeting CD40-ligand
(CD40L or CD154) being developed for the prevention of allograft
and xenograft rejection and for the treatment of autoimmune
diseases. A Phase 1 study of TNX-1500 is expected to be initiated
in the first half of 2023. Tonix’s infectious disease pipeline
consists of a vaccine in development to prevent smallpox and
monkeypox, next-generation vaccines to prevent COVID-19, and a
platform to make fully human monoclonal antibodies to treat
COVID-19. TNX-801, Tonix’s vaccine in development to prevent
smallpox and monkeypox, also serves as the live virus vaccine
platform or recombinant pox vaccine (RPV) platform for other
infectious diseases. A Phase 1 study of TNX-801 is expected to be
initiated in Kenya in the first half of 2023. Tonix’s lead vaccine
candidate for COVID-19 is TNX-1850, a live virus vaccines based on
Tonix’s recombinant pox live virus vector vaccine platform. A Phase
1 study of the COVID-19 vaccine is expected to be initiated in the
second half of 2023.
*All of Tonix’s product candidates are
investigational new drugs or biologics and have not been approved
for any indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; delays and uncertainties caused
by the global COVID-19 pandemic; risks related to the timing and
progress of clinical development of our product candidates; our
need for additional financing; uncertainties of patent protection
and litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Tonix does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in the Annual Report on Form 10-K for the
year ended December 31, 2021, as filed with the Securities and
Exchange Commission (the “SEC”) on March 14, 2022, and periodic
reports filed with the SEC on or after the date thereof. All of
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com (862)
904-8182
Olipriya Das, Ph.D. (media)Russo
PartnersOlipriya.Das@russopartnersllc.com (646) 942-5588
Peter Vozzo (investors)ICR
Westwickepeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024